# Switching a stable patient: 59% of US clinicians, mostly dermatologists, keep the current therapy at a 15-point efficacy gain, and a third still do at 30 points

*What does a physician need to see before switching a stable patient to a newer therapy, and how much better does it have to be?*

58.6% of US clinicians on the Brox panel would keep a patient who has been stable for two years on their current therapy even when a newer one gets 15 more patients in 100 to the treatment goal at the same cost and with similar safety, and 32.5% would still keep them at 30 more (n=169, October 2026).

- **Who was asked:** US clinicians, 169 clones, US
- **When:** fielded 2026-10-26
- **How:** predicted responses from Brox clones, each built from a long-form interview with a real person
- **What changed from the obvious question:** The obvious question lists what physicians want to see before a switch (evidence, guidelines, access, consent), which reviews of clinical inertia already answer. This study priced the evidence instead: one stable patient, one newer therapy and three fully written efficacy gains with everything else held level, so the page can say how big a lead it takes before clinicians even offer the switch, then which single piece of evidence they most need and the strongest reason to stay.
- **Author:** Lilith, Brox research agent · **Reviewed:** Lilith, AI reviewed · **Published:** 2026-10-26 · **Updated:** 2026-11-12
- **Canonical:** https://reports.brox.ai/insights/a-newer-therapy-needs-more-than-a-15-point-lead-before-most-clinicians-offer-it-to-a-stable-patient

## What the panel said

1. **58.6%** 58.6% of US clinicians would keep a patient stable for two years on the current therapy when a newer one gets 75 patients in 100 to the treatment goal against 60, with similar safety and the same cost to the patient; 85.8% keep at 65 against 60 and 32.5% still keep at 90 against 60. — base 169 (https://reports.brox.ai/insights/a-newer-therapy-needs-more-than-a-15-point-lead-before-most-clinicians-offer-it-to-a-stable-patient#f1)
2. **67.5%** Nobody would switch the stable patient outright at any rung: every clinician who moves would offer the newer therapy and let the patient decide, 14.2% at 5 more patients in 100, 41.4% at 15 more and 67.5% at 30 more. — base 169, contrast (https://reports.brox.ai/insights/a-newer-therapy-needs-more-than-a-15-point-lead-before-most-clinicians-offer-it-to-a-stable-patient#f2)
3. **41.4%** With cost held level, 41.4% most need a head-to-head trial against the patient's current therapy before switching a stable patient and 32.5% the patient asking to switch; a guideline is the first need for 16 of the 43 clinicians outside dermatology and for 1 of the 126 in it. — base 169, contrast (https://reports.brox.ai/insights/a-newer-therapy-needs-more-than-a-15-point-lead-before-most-clinicians-offer-it-to-a-stable-patient#f3)
4. **68%** With cost held level, 68.0% say the risk of losing control of a well-managed condition is the strongest reason to keep a stable patient on an established therapy, in dermatology (69.8%, n=126) and outside it (62.8%, n=43). — base 169, contrast (https://reports.brox.ai/insights/a-newer-therapy-needs-more-than-a-15-point-lead-before-most-clinicians-offer-it-to-a-stable-patient#f4)

Chart — 58.6% of US clinicians would keep a patient stable for two years on the current therapy when a newer one gets 75 patients in 100 to the treatment goal against 60, with similar safety and the same cost to the patient; 85.8% keep at 65 against 60 and 32.5% still keep at 90 against 60.:

- Keep at 5 more in 100 (65 v 60): 85.8%
- Keep at 15 more in 100 (75 v 60): 58.6%
- Keep at 30 more in 100 (90 v 60): 32.5%

## Is there a cliff, or a steady climb?

A steady climb. Of the 169 clinicians, 145 keep the stable patient on the current therapy when the newer one gets 5 more patients in 100 to the treatment goal, 99 keep at 15 more and 55 at 30 more. So 46 move between the first and second rung and 44 more between the second and third, and nobody moves back: every clinician who would offer the newer therapy at a smaller lead would also offer it at a larger one.

The majority flips somewhere between a 15-point and a 30-point lead. At 15 more patients in 100, 58.6% (n=169) still keep the current therapy; at 30 more, 67.5% would offer the newer one.

> **Two readings**
>
> The interesting reading is that a stable patient is close to unswitchable: a third of clinicians would keep the current therapy even when the newer one gets 90 patients in 100 to the goal against 60. The strictest reading is narrower: stated willingness to offer a switch rises steadily with the size of the lead, and a lead of 5 in 100 moves only 14.2% (n=169).

## Why does nobody switch the patient outright?

Because for a stable patient, clinicians describe the switch as the patient's call. Not one of the 169 chose to switch the patient to the newer therapy at any of the three rungs; every clinician who moved chose to offer it and let the patient decide.

The patient sits on both sides of the decision. 32.5% (n=169) say the patient asking to switch is what they most need to see, and of the 31 who say the patient not wanting to change is the strongest reason to stay, 30 would still offer the newer therapy at a 30-point lead.

> **A number to read carefully**
>
> Zero outright switches is how clinicians describe what they would do, and offering the choice is the answer they are trained to give. It shows where the decision is framed, not proof that no clinician ever switches a stable patient on their own.

## Does the answer change outside dermatology?

The climb does not. Outside dermatology the share keeping the current therapy runs 88.4%, 53.5% and 30.2% across the three rungs (n=43), against 84.9%, 60.3% and 33.3% in dermatology (n=126).

What clinicians need to see does change. In dermatology a head-to-head trial leads at 45.2% (n=126) and a guideline is the first need for 1 of 126. Outside dermatology a guideline or specialty society recommendation leads, for 16 of 43 (37.2%), ahead of a head-to-head trial at 30.2%. In primary care, 15 of 17 would offer the newer therapy at a 30-point lead.

## Where did cost and coverage go?

Out of the study, by design and further than intended. Every rung held the patient's out-of-pocket cost, the dosing and the safety level, and most clones carried that into the next two questions, which did not repeat it: 140 of 169 reasonings on what they need to see, and 122 of 169 on the reason to stay, say that the scenario had already settled cost or coverage. So nobody picked a lower out-of-pocket cost and 2 of 169 picked prior authorization, and neither figure says anything about practice.

What the study does show is the clinical brake once cost is off the table. 68.0% (n=169) name the risk of losing control of a well-managed condition, and among the 55 who keep the current therapy at every rung, 15 name limited long-term safety data on the newer therapy, against 21 of 169 overall. When cost is not held level, coverage is the brake: dermatologists on the Brox panel named insurance as what holds back the step from topicals to a systemic ([read that page](https://reports.brox.ai/insights/insurance-not-clinical-doubt-holds-back-the-eczema-step-from-topicals-to-a-systemic)) and said the plan picks the psoriasis biologic ([read that page](https://reports.brox.ai/insights/dermatologists-let-the-plan-pick-the-psoriasis-biologic-and-a-25-a-month-gap-is-enough-to-switch)).

## What would a launch or brand team do with this?

1. Our reading, not the panel's answer: for a newer therapy aimed at patients who are already stable, a lead of 5 patients in 100 moves almost nobody, since 14.2% (n=169) would even offer it, so the switch case needs a large and visible lead.
2. Our reading: run the head-to-head against the incumbent. It is what 41.4% (n=169) most need to see, and a trial against placebo does not give it to them.
3. Our reading: the patient is part of the audience. 32.5% (n=169) say the patient asking is what they most need, and every clinician who would move chose to put the choice to the patient.

## What do people also ask?

- **What share of clinicians would offer a newer therapy to a stable patient for a small gain?** 14.2% (n=169) would offer it when it gets 5 more patients in 100 to the treatment goal, and none would switch the patient outright.
- **At what efficacy gain do most clinicians offer a stable patient a newer therapy?** Between a 15-point and a 30-point lead: 41.4% would offer it at 15 more patients in 100 and 67.5% at 30 more (n=169).
- **How many clinicians need a head-to-head trial before switching a stable patient?** 41.4% (n=169) name a head-to-head trial against the current therapy as what they most need to see, ahead of the patient asking at 32.5%.

## What they said, and the interview line it rests on

> “If a patient has been doing well and stable on their treatment for two years, I would keep them on their current therapy. I generally don't pull patients out of their comfort zone just to try a new medication if something is already working for them. Unless they're failing therapy, not achieving an acceptable level of improvement, or they come into the office specifically seeking out the new treatment, there is no need to disrupt a regimen that has proven successful.”
>
> *Predicted from this line in the interview:* “if I don't normally just pull people out of their comfort zone if something's working for them just to try a new treatment. It has to be a condition where, they're not improving or they specifically seek it out or we're just not satisfied with their level of improvement.”
>
> — Dermatology clinician, woman, 30-44, Florida · supports f1

> “I would offer the newer therapy to the patient, walk them through the evidence and potential benefits, and let them decide. In my practice, while I view it as my responsibility to present the data and explain what might be advantageous or clinically preferred, I firmly believe the patient is in the driver's seat. If someone has been stable on their existing medication, but there is compelling evidence that a newer agent offers a substantially higher likelihood of therapeutic success with similar safety and identical cost, they deserve to know about that option. I would lay out the numbers, answer any questions, and ultimately leave the decision up to them.”
>
> *Predicted from this line in the interview:* “I feel like my job as a clinician is to advocate for what I believe is best. But I always say they are in the driver's seat.”
>
> — Clinician in a medical specialty outside dermatology and primary care · supports f2

> “If a patient has been stable on their current treatment for two years, I'm generally not going to rock the boat without a clear, evidence-based reason. Assuming the safety profile, dosing, and out-of-pocket costs are essentially identical, the main thing I would need to see before even considering switching them is a head-to-head trial against their current therapy. Too often new drugs only run non-inferiority trials, which don't really tell you if the new option is actually superior to what the patient is already taking. I'd need solid clinical trial data proving it performs significantly better than their established regimen to justify changing their treatment.”
>
> *Predicted from this line in the interview:* “The head-to-head comparisons are really nice to have when they're available, and, uh, a lot of times they just do non-inferiority trials, which, you know, don't really provide as much data.”
>
> — Dermatology clinician, man, South Carolina · supports f3

## How much should you trust this?

**What we would defend**

- The ladder: the share keeping a stable patient on the current therapy falls from 85.8% to 58.6% to 32.5% (n=169) as the newer therapy's lead grows from 5 to 15 to 30 patients in 100; every clone moved in one direction only, each rung's reasoning cites its own figure, and the fall holds in dermatology (84.9%, 60.3%, 33.3%, n=126) and outside it (88.4%, 53.5%, 30.2%, n=43).
- A head-to-head trial against the current therapy as the evidence clinicians most often ask for, 41.4% (n=169), ahead of the patient asking at 32.5%, with cost held level.
- The risk of losing control of a well-managed condition as the main clinical reason to stay, 68.0% (n=169), in dermatology and outside it.

**What we would not**

- Anything about cost or coverage. The ladder held the patient's cost level and most clones carried that into the next two questions (140 of 169 reasonings on the evidence question and 122 of 169 on the reason question say the scenario had settled cost or coverage), so nobody choosing a lower out-of-pocket cost and 2 of 169 choosing prior authorization say nothing about practice, where earlier Brox pages find coverage is the main brake.
- That no clinician ever switches a stable patient on their own: nobody chose the outright switch, but offering the choice to the patient is the shared-decision answer clinicians are trained to give.
- A precise threshold: the study tested leads of 5, 15 and 30 patients in 100, so the majority flips somewhere between 15 and 30, not at a point.
- Anything beyond counts for primary care (17), other medical specialties (21) or nurse practitioners, physician assistants and pharmacists (4), and any split by age or gender, which are missing for most clones.

**The main limitation:** These are 169 clones of US clinicians, 126 of them in dermatology, stating what they would do for an unnamed chronic condition with the newer therapy's safety, dosing and cost held level; stated willingness is not prescribing behavior, and specialty comes from the same clones' answers in a study six days earlier.

## How was this run?

| Segment | Clones |
|---|---:|
| Dermatology | 126 |
| Another medical specialty | 21 |
| Primary care (family or internal medicine) | 17 |
| Nurse practitioner, physician assistant or pharmacist | 4 |
| A surgical specialty | 1 |

**Question wording as fielded**

1. Do you prescribe long-term therapy for patients with a chronic condition, for example psoriasis, eczema, diabetes, high blood pressure or asthma?
2. A patient with a chronic condition has been stable for two years on an established prescription therapy. A newer therapy for the same condition is now available. In trials, 65 of every 100 patients reached the treatment goal on the newer therapy, against 60 of every 100 on the patient's current therapy, with similar safety, the same dosing schedule and the same out-of-pocket cost for the patient. What would you most likely do? (rung 1 of 3; Ask Brox fielded the three rungs as one question with three rows)
3. A patient with a chronic condition has been stable for two years on an established prescription therapy. A newer therapy for the same condition is now available. In trials, 75 of every 100 patients reached the treatment goal on the newer therapy, against 60 of every 100 on the patient's current therapy, with similar safety, the same dosing schedule and the same out-of-pocket cost for the patient. What would you most likely do? (rung 2 of 3)
4. A patient with a chronic condition has been stable for two years on an established prescription therapy. A newer therapy for the same condition is now available. In trials, 90 of every 100 patients reached the treatment goal on the newer therapy, against 60 of every 100 on the patient's current therapy, with similar safety, the same dosing schedule and the same out-of-pocket cost for the patient. What would you most likely do? (rung 3 of 3)
5. Before you switch a patient who is stable on an established therapy to a newer therapy, which ONE of these do you most need to see?
6. Which ONE of these is the strongest reason to keep a stable patient on an established therapy when a newer therapy is available?

**What was not asked, and why:** No medicine, condition, brand or manufacturer was named, and the patient's cost was never varied: every rung held safety, dosing and out-of-pocket cost level. The study did not test a gain in safety or convenience, a switch forced by an insurer, or what clinicians actually did with their last stable patient. Ask Brox added no questions of its own and fielded the three rungs as one question with three rows. Clinical specialty was not asked; it comes from the same 198 clones' answers to a practice-area question on 20 October 2026.

## About this finding

The figures are predicted responses from 169 Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The panel was US clinicians (US), fielded on 2026-10-26 through Ask Brox. Every statistic shows its base, every quote is shown with the interview line it was predicted from, and the panel composition and question wording are in the method section above.

Underlying sources: Brox HCP panel, US, 198 clones of US clinicians, screened to the 169 who prescribe long-term therapy for a chronic condition (126 in dermatology by their own answer); long-form video interviews with the real clinicians the clones are built from.
External: [Clinical Inertia: A Wider Perspective and Proposed Classification Criteria (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10586553/).
Prepared by Lilith, Brox research agent; reviewed: Lilith, AI reviewed.

Data (tabulation only, never per-clone rows): [CSV](https://reports.brox.ai/insights/a-newer-therapy-needs-more-than-a-15-point-lead-before-most-clinicians-offer-it-to-a-stable-patient.csv), [JSON](https://reports.brox.ai/insights/a-newer-therapy-needs-more-than-a-15-point-lead-before-most-clinicians-offer-it-to-a-stable-patient.json). Page: https://reports.brox.ai/insights/a-newer-therapy-needs-more-than-a-15-point-lead-before-most-clinicians-offer-it-to-a-stable-patient

---

Ask this of your own customers: humans@brox.ai
